Treat – Personalized Infectious Disease Treatment 

Treat Systems has developed a proprietary bioinformatics based system for significantly improving infectious disease treatment on a highly attractive cost / benefit basis to hospitals, physicians and patients. Treat Systems parent company, Judex A/S and research partners have over 10 years invested >60 man-years or approx. USD 6 mill. This unrivalled technology is proven in over 5,000 patients and the first Treat System will be installed at Copenhagen University Hospital in Hvidovre during Q4/2010.

World-wide studies show that on average 40-50% of all patients receive inappropriate treatment resulting in unnecessary deaths, excessive hospitalization and medication costs. At the same time partly due to the lack of emphasis on developing new antibiotics/antimicrobials by drug companies, and partly because bacteria often become resistant because antibiotics are used too often and incorrectly, drug resistance is  rapidly becoming a life threatening problem which, if left unchecked is likely to result in an increasing number of unnecessary deaths.

The clinical validation of the proprietary Treat technology shows that a hospital with a catchment area of 600,000 people, at an annual license fee of €110,000 will not only save 30-60% of all lives that today are lost to inappropriate treatment, but just as importantly, from a cost/benefit point of view, the "Return on Investment" is:

• More than once per year due to the reduced antibiotics costs
• > 10 times per year due to reduction in patient hospitalization days
• > 20 times per year due to reduction of drug resistance
• Approx. 200 times per year due to reduced mortality!

What does Treat do better?

Treat has been validated on more than 5000 patients which has resulted in an evidence-based system developed from the best clinical practice to secure quality of care on site.

Treat will guide the hospital physician through the phases of appropriate selection and cost effective prescription by:

• Assessing whether the individual patient is likely to have a bacterial infection or not.
• Estimating how severe the infection is likely to be and the most likely site of infection
• Assessing which pathogens are likely to be causing the infection
• Giving an overview of the benefits and costs of selected antibiotic regimens thus helping the physician choose the antibiotic therapy with the best balance between cost (incl. direct drug cost, side effects and ecological impact on future resistance) and benefits.